Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
(b)
On January 10, 2023, Kirsten Flowers notified Kura Oncology, Inc. (the
"Company") of her intention to resign from her position as the Company's Chief
Commercial Officer, effective as of January 27, 2023 (the "Separation Date"), in
order to pursue other opportunities.
(e)
On January 11, 2023, in connection with Ms. Flowers' resignation, the Company
and Ms. Flowers entered into a Transition and Separation Agreement (the "Flowers
Agreement") pursuant to which Ms. Flowers (i) will continue in employment with
the Company through the Separation Date, (ii) will be entitled to receive,
subject to Ms. Flowers' execution and non-revocation of a customary release of
claims in favor of the Company and compliance with her obligations under the
Flowers Agreement, (a) a cash amount equal to 6 months of her base salary in
effect as of the Separation Date, and (b) Ms. Flowers' 2022 annual cash bonus,
as determined by the Board of Directors of the Company in its sole discretion
based on Ms. Flowers' actual achievement of her corporate and individual
performance goals for calendar year 2022, and (iii) agreed to a non-compete for
a period of six months following the Separation Date.
The foregoing description of the Flowers Agreement is not complete and is
subject to and qualified in its entirety by reference to the complete text of
the Flowers Agreement, a copy of which the Company intends to file with the
Securities and Exchange Commission as an exhibit to the Company's Quarterly
Report on Form 10-Q for the quarterly period ending March 31, 2023.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
KURA ONCOLOGY, INC. 
